KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to $6.3 million.

  • Evolent Health's Depreciation and Depletion fell 1600.0% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year decrease of 1016.39%. This contributed to the annual value of $30.3 million for FY2024, which is 648.15% down from last year.
  • As of Q3 2025, Evolent Health's Depreciation and Depletion stood at $6.3 million, which was down 1600.0% from $6.4 million recorded in Q2 2025.
  • Evolent Health's 5-year Depreciation and Depletion high stood at $8.9 million for Q4 2022, and its period low was $6.3 million during Q3 2025.
  • For the 5-year period, Evolent Health's Depreciation and Depletion averaged around $7.6 million, with its median value being $7.6 million (2021).
  • Per our database at Business Quant, Evolent Health's Depreciation and Depletion skyrocketed by 1470.59% in 2021 and then tumbled by 1898.73% in 2025.
  • Evolent Health's Depreciation and Depletion (Quarter) stood at $7.8 million in 2021, then grew by 14.1% to $8.9 million in 2022, then decreased by 14.61% to $7.6 million in 2023, then fell by 2.63% to $7.4 million in 2024, then fell by 14.86% to $6.3 million in 2025.
  • Its Depreciation and Depletion stands at $6.3 million for Q3 2025, versus $6.4 million for Q2 2025 and $7.3 million for Q1 2025.